BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20498647)

  • 1. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.
    Rager A; Frey N; Goldstein SC; Reshef R; Hexner EO; Loren A; Luger SM; Perl A; Tsai D; Davis J; Vozniak M; Smith J; Stadtmauer EA; Porter DL
    Bone Marrow Transplant; 2011 Mar; 46(3):430-5. PubMed ID: 20498647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
    Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
    Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
    Rodriguez V; Anderson PM; Trotz BA; Arndt CA; Allen JA; Khan SP
    Pediatr Blood Cancer; 2007 Aug; 49(2):212-5. PubMed ID: 16261610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.
    Willenbacher W; Basara N; Blau IW; Fauser AA; Kiehl MG
    Br J Haematol; 2001 Mar; 112(3):820-3. PubMed ID: 11260089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
    Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
    Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.
    Przepiorka D; Kernan NA; Ippoliti C; Papadopoulos EB; Giralt S; Khouri I; Lu JG; Gajewski J; Durett A; Cleary K; Champlin R; Andersson BS; Light S
    Blood; 2000 Jan; 95(1):83-9. PubMed ID: 10607689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
    Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
    Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
    Lee SJ; Zahrieh D; Agura E; MacMillan ML; Maziarz RT; McCarthy PL; Ho VT; Cutler C; Alyea EP; Antin JH; Soiffer RJ
    Blood; 2004 Sep; 104(5):1559-64. PubMed ID: 15138163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
    Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
    Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
    Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD.
    Jacobsohn DA; Vogelsang GB
    Drugs; 2002; 62(6):879-89. PubMed ID: 11929336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid-refractory graft-vs.-host disease: past, present and future.
    Carpenter PA; Sanders JE
    Pediatr Transplant; 2003; 7 Suppl 3():19-31. PubMed ID: 12603689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
    Teachey DT; Bickert B; Bunin N
    Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
    Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
    Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
    Fang J; Hu C; Hong M; Wu Q; You Y; Zhong Z; Li W; Zou P; Hu Y; Xia L
    Biol Blood Marrow Transplant; 2012 May; 18(5):754-62. PubMed ID: 21963619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease.
    Nogueira MC; Azevedo AM; Pereira SC; Ferreira JL; Lerner D; Lobo AM; Tavares RC; Tabak DG; Lorenzi N; Renault IZ; Bouzas LF
    Braz J Med Biol Res; 2007 Dec; 40(12):1623-9. PubMed ID: 17713663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
    Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
    Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
    Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
    Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Salvage treatment with infliximab of steroid-resistant graft-versus-host disease in allogeneic transplanted patients].
    Motlló C; Ferrà C; López L; Morgades M; Batlle M; Ribera JM
    Med Clin (Barc); 2011 Jun; 137(3):115-8. PubMed ID: 21543091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab for GVHD therapy in children.
    Sleight BS; Chan KW; Braun TM; Serrano A; Gilman AL
    Bone Marrow Transplant; 2007 Sep; 40(5):473-80. PubMed ID: 17618323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.